Maridebart cafraglutide is an investigational drug developed by Amgen for the treatment of obesity. It is an agonist of the GLP-1 receptor and an antagonist of the glucose-dependent insulinotropic polypeptide receptor. From Wikipedia
Novo Nordisk and Eli Lilly face new competition from Amgen's monthly injectable, shaking up the obesity treatment landscape.
/medriva/media/post_banners/content/uploads/2024/02/amgen-maridebart-cafraglutide-obesity-drug-phase-1-trial-results-20240205191313.jpg)
